Fulgent Genetics Inc (FLGT)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $688.98M
Last updated: Nov 17, 2026 at 11:06 AM ET
Fulgent Genetics Inc (FLGT) Stock Forecast
Analysts expect Fulgent Genetics (FLGT) to earn -$1.70 per share in the fiscal year ending Dec 31, 2026, on revenue of $335.10M. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$1.36.
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 9.6%.
- Fiscal year ending Dec 31, 2026
- -$1.70
- EPS consensus, revenue $335.10M
- Fiscal year ending Dec 31, 2027
- -$1.36
- EPS consensus, revenue $367.40M
- Next report
- Feb 25, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.70 | -$1.70 to -$1.70 | 1 | $335.10M | $335.10M to $335.10M | 1 |
| Dec 31, 2027 | -$1.36 | -$1.36 to -$1.36 | 1 | $367.40M | $367.40M to $367.40M | 1 |
Quarterly Estimates
The EPS consensus rises from -$0.69 for the quarter ending Dec 31, 2026 to -$0.33 for the quarter ending Mar 31, 2027.
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.69 | N/A | 3 | $89.96M | $86.44M to $92.61M | 3 |
| Mar 31, 2027 | -$0.33 | -$0.33 to -$0.33 | 1 | $89.00M | $89.00M to $89.00M | 1 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 1 upward and 2 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 1 |
| Fiscal year ending Dec 31, 2027 | 0 | 1 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$2.27.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$1.70 | -$2.27 | -$2.27 | -$2.27 | -$2.27 | N/A |
| Fiscal year ending Dec 31, 2027 | -$1.36 | -$1.38 | -$1.38 | -$1.38 | -$1.38 | N/A |
| Quarter ending Mar 31, 2027 | -$0.33 | -$0.50 | -$0.50 | -$0.50 | -$0.50 | N/A |
Frequently Asked Questions About FLGT
What is the FLGT stock forecast?
Consensus analyst estimates put Fulgent Genetics's EPS at -$1.70 for the fiscal year ending Dec 31, 2026, on revenue of $335.10M.
What EPS do analysts expect from FLGT next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.70, with estimates from -$1.70 to -$1.70 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$1.36, with estimates from -$1.36 to -$1.36 from 1 analyst.
What revenue do analysts expect from Fulgent Genetics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $335.10M, with estimates from $335.10M to $335.10M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $367.40M, with estimates from $367.40M to $367.40M.
How many analysts cover FLGT?
1 analyst estimates EPS for Fulgent Genetics for the fiscal year ending Dec 31, 2026.
FLGT pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts